Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results
- Positive data from bexotegrast INTEGRIS-IPF 320 mg dose group demonstrated a continued favorable safety profile and statistically significant increases in FVC - INTEGRIS-IPF 320 mg dose 24-week data expected in the second quarter of 2023 - $287.5 million …